

When is Multimodality Assessment of Cardiac Function Needed?



Craig Broberg, MD MCR
Knight Cardiovascular Institute,
Oregon Health & Science University

No Disclosures
Gadolinium is off-label
for cardiac MR


1

Multimodality methods at our disposal







2

Multimodality methods at our disposal



3

Multimodality methods at our disposal



4

Multimodality Comparisons

Metanalysis involving 65 studies, mostly echo compared to CMR
Only structurally normal LVs included (ie no congenital)



Rigolli M. Open Heart 2016;3:e000388

5

Multimodality Comparisons

Metanalysis involving 65 studies, mostly echo compared to CMR
Only structurally normal LVs included (ie no congenital)

| <u>Difference</u> <u>vs. CMR</u> | <u>N</u> | <u>LVEDV</u> | <u>LVESV</u> |
|-------------------------------------|----------|--------------|--------------|
| 2D Echo | 1683 | -33 | -16 |




Rigolli M. Open Heart 2016;3:e000388

6

Multimodality Comparisons

Metanalysis involving 65 studies, mostly echo compared to CMR
 Only structurally normal LVs included (ie no congenital)
 Era didn't matter (<2005 vs. after 2009)

| <u>Difference vs. CMR</u> | <u>N</u> | <u>LVEDV</u> | <u>LVESV</u> |
|---------------------------|----------|--------------|--------------|
| 2D Echo | 1683 | -33 | -16 |
| 2D CE Echo | 283 | -18 | -8 |
| 3D Echo | 1159 | -14 | -6 |



Rigolli M. Open Heart 2016;3:e000388

7

Sources of Error

ECHO

Apex foreshortening
 Endocardial dropout

Lower spatial resolution

CMR

Basal plane interpretation

CT

Beta blocker/NTG
 Fluid bolus


Lower temporal resolution




8

Methodologic Differences


ECHO



CMR



CT



9

Methodologic Differences

ECHO

Long axis

CMR

Short axis*

CT

Long/short axis*



* Variable use

10

Methodologic Differences

ECHO

Long axis

Papillaries and
trabeculations
excluded

CMR

Short axis*

Papillaries and
trabeculations
included*

CT

Long/short axis*

Papillaries and
trabeculations
included



* Variable use

11

Methodologic Differences

ECHO

Long axis

Papillaries and
trabeculations
excluded

Outflow tract
excluded

CMR

Short axis*

Papillaries and
trabeculations
included*

Outflow tract
included

CT

Long/short axis*

Papillaries and
trabeculations
included

Outflow tract
included*




* Variable use

12

Papillaries and Trabeculations

Sometimes the differences can be extensive



13

Temporal Resolution: Frame count

Echo = 60 frames, CMR = 30 frames, CT = 10 frames




14

Temporal Resolution: Frame count

Echo = 60 frames, CMR = 30 frames, CT = 10 frames

Volume over the Cardiac Cycle



15

Temporal Resolution: Acquisition Time


Echo Single heart beat per image



CT 1-5 heart beats per image



CMR 8-10 heart beats/breath hold (~12 breath holds)




16

Temporal Resolution: Acquisition Time

Echo Single heart beat per image




CT 1-5 heart beats per image



Dependent on respiratory motion

CMR 8-10 heart beats/breath hold (~12 breath holds)



Takes longer, but less
Dependent on
respiratory
motion



17

CMR Sensitive to Volumetric Change

MERIT-HF: Metoprolol vs. Placebo (randomized, double-blind) for 6 months

CMR pre and post treatment

| | <u>Baseline</u> | <u>6 months</u> | |
|--------|--------------------------|-----------------------|-------------|
| LVEDVI | 150 ml/m ² | 126 ml/m ² | (p = 0.01) |
| LVEF | 29% | 37% | (p = 0.005) |
| | (no change with placebo) | | |

Groenning BA, J Am Coll Cardiol. 2000 Dec;36(7):2072-80



18

CMR Sensitive to Volumetric Change

MERIT-HF: Metoprolol vs. Placebo (randomized, double-blind) for 6 months

CMR pre and post treatment

| | <u>Baseline</u> | <u>6 months</u> | | |
|--------|--------------------------|-----------------------|-------------|---------------|
| LVEDVI | 150 ml/m ² | 126 ml/m ² | (p = 0.01) | N = 22 |
| LVEF | 29% | 37% | (p = 0.005) | |
| | (no change with placebo) | | | N = 19 |

Groenning BA, J Am Coll Cardiol. 2000 Dec;36(7):2072-80

ANZ HF Trial (ECHO)

N= 415

Circ 1995;92:212-218

MERIT-HF (Clinical End Points) **N= 3,998**



When is functional assessment relevant?

Clinical Decisions that may depend on volume/function

- Timing of valve surgery

- Device implantation (ICD)

- Determining need for medical therapy (is this heart “normal”)


- Prognosis

These can all be addressed with echocardiography




21

When CT?




22

CT for valves



23

When CMR?



24

CMR is an adjunct to Echo

From Guideline Statements: "CMR is useful when

"echocardiography is inconclusive ..."

"issues are not satisfactorily addressed ..."

"etiology is unclear ..."

"other means do not provide ..."

"risk remains borderline ..."



25

Clinical Questions for which CMR is used

CMR functional assessment especially for

Inadequate echo quality

Quantification of valve regurgitation

Myocardial tissue characterization



RV quantification/Shunts



26

CMR Assessment of Valve Regurgitation

Less Qualitative but more Quantitative



27

CMR Assessment of Valve Regurgitation

“The most challenging aspect in the management of MR is accurate quantification of severity and consequent decision regarding timing of intervention”



Kar S, Sharma R, JACC 2015 MAR 24:65(11):1089

28

CMR Assessment of Valve Regurgitation

CMR vs. Echo done in 103 patients with mitral regurgitation,
 MR severity agreement between the methods was weak
 Only 22% of those with severe MR by echo had severe MR by CMR
 CMR had better reproducibility (90% vs. 61%)




Uretsky S, JACC 2015 65(11):1078-88

29

CMR Assessment of Valve Regurgitation

CMR vs. Echo done in 103 patients with mitral regurgitation,
 38 underwent surgery
 LV remodeling was assessed ~6 months later (“gold standard”)
 Degree of remodeling more predictive by CMR, not by echo



Uretsky S, JACC 2015 65(11):1078-88

30

Valve Guidelines

1B “CMR is indicated in patients with . . . **suboptimal echo images** for the assessment of LV function and measurement of AR severity.”


1B “CMR is indicated in patients with chronic primary MR to assess . . . MR severity and **when not satisfactorily addressed by TTE.**”



31

Valve Stenosis

CMR less advantageous than echo
Velocity can be measured
Less sensitive to finding peak gradient




32



33

Myocardial Imaging (not just function)



34

Cardiomyopathy Assessment with CMR

Etiology of myocardial change



Overall Prognostication

Arrhythmia prediction



35

LGE and T1 mapping



T1 is an independent predictor of events in CAD

36

Extracellular Volume Fraction

ECV detects fibrosis burden in the setting of:

- dilated cardiomyopathy
- atrial fibrillation
- hypertrophic cardiomyopathy
- muscular dystrophy
- aortic stenosis
- amyloidosis
- mitral valve prolapse



Iles L, J Am Coll Cardiol. 2008;52:1574-1580
 Ling LH, J Am Coll Cardiol. 2012;60:2402-2408
 Brouwer WP, J Cardiovasc Magn Reson. 2014;16:28
 Florian A, J Cardiovasc Magn Reson. 2014;16:81
 Aus dem Siepen F, European heart journal cardiovascular Imaging. 2014
 de Meester de Ravenstein C, J Cardiovasc Magn Reson. 2015;17:015-0150
 Iles L, J Am Coll Cardiol. 2011;57:821-828

37

“Parametric mapping should be considered in the diagnostic evaluation of all patients with heart failure and unexplained troponin elevation.”





Messroghli D, J CMR (2017) 19:75

38

“Parametric Mapping” for Myocardium

Not just seeing the function, but seeing what’s in the tissue



Most accurate and best predictor in amyloidosis

Austin B, JACC Cardiovasc Imaging. 2009 Dec;2(12):1369-77.



39

“Parametric Mapping” for Myocardium




Fig. 1 Typical appearance of T1, T2, T2*, and ECV maps in healthy subjects and in patients with myocardial disease. Arrows denote relative change in respective parametric maps. Courtesy of P.K

40



41

Arrhythmia Prediction (VT/SCD/ICD shock)

Metanalysis of thousands of patients:

DCM LGE present in 44%, mean follow up 3 years

Any ventricular arrhythmia

| | | |
|----------|-----|-----------|
| with LGE | 21% | 6.5%/year |
|----------|-----|-----------|

| | | |
|-------------|------|-----------|
| without LGE | 4.7% | 1.6%/year |
|-------------|------|-----------|

HR=6.7; p < 0.001

Di Marco A, JACC Heart Fail 2017;5:28-38



42

Arrhythmia Prediction (VT/SCD/ICD shock)

Metanalysis of thousands of patients:

DCM LGE present in 44%, mean follow up 3 years

Any ventricular arrhythmia

with LGE 21% 6.5%/year

without LGE 4.7% 1.6%/year

HR=6.7; $p < 0.001$

Di Marco A, JACC Heart Fail 2017;5:28-38

HCM LGE present in 60%, mean follow up 3.1 years

Cardiac death

with LGE 4.9%

without LGE 1.2%

OR=2.9; $p = 0.047$

Green JJ, JACC: CVI Apr 2012, 5 (4) 370-377




43

Echo vs. CMR in risk prediction

409 Italians with cardiomyopathy (52% ischemic, 48% non-ischemic)

CMR and Echo done at baseline. CMR volumes were bigger



Pontone G, Circ Cardiovasc Imaging. 2016 Oct;9(10). pii: e004956



44

Echo vs. CMR in risk prediction

409 Italians with cardiomyopathy (52% ischemic, 48% non-ischemic)

Followed for ~1.5 years

25% had MACE (19% ventricular arrhythmias)

Higher LVEDV (both echo and CMR) was a significant predictor

Strongest prediction was based on CMR volume + LGE



Pontone G, Circ Cardiovasc Imaging. 2016 Oct;9(10). pii: e004956

45

Guidelines

DCM

I (C) “CMR imaging is recommended to . . . characterize cardiac tissue in subjects with **inadequate echocardiographic images** or where the echocardiographic findings are inconclusive or incomplete.”

IIA (B) “CMR should be considered in patients with ventricular arrhythmias when **echocardiography does not provide accurate assessment** of LV and RV function and/or evaluation of structural changes.”



46

Guidelines

DCM

I (C) “CMR imaging is recommended to . . . characterize cardiac tissue in subjects with **inadequate echocardiographic images** or where the echocardiographic findings are inconclusive or incomplete.”

IIA (B) “CMR should be considered in patients with ventricular arrhythmias when **echocardiography does not provide accurate assessment** of LV and RV function and/or evaluation of structural changes.”

HCM

IIB (C) “When **SCD risk stratification is inconclusive** after documentation of the conventional risk factors, CMR imaging with assessment of LGE may be considered in resolving clinical decision making.”



47



48

RV Visualization

CMR is well suited for RV

Not limited by acoustic windows

No assumptions needed about geometry

Useful for

RV cardiomyopathies

Pulmonic and tricuspid valves

Pulmonary hypertension

Congenital heart disease





Intervention guidelines are mostly based on CMR based assessment

49

Right Ventricular Volume and Function


CMR excels in RV imaging



50

Strain by CMR?

Feature tracking algorithms. Temporal resolution is different than echo



51



52

Take Home Points on Multimodality Imaging

Echo for all, CMR and CT for specific circumstances

Echo will typically underestimate the ventricular volumes relative to CMR

CMR is more reproducible and quantitative volumes and valve regurgitation

CMR provides assessment of myocardial tissue which can be prognostic

Functional CT is especially useful for metal valves, metal implants and when CMR is unusable



53



54



55